Tempo Therapeutics Closes Oversubscribed $14.5 Million Financing to Advance MAP(TM) Regenerative TechnologyFinancing follows FDA De Novo submission and publication of positive first-in-human clinical resultsCompany strengthens leadership and Board as it advances surgical reconstruction toward commercialization and evaluates opportunities in regenerative aesthetics
